ADYX (Adynxx) Cyclically Adjusted PS Ratio: (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADYX Adynxx Inc ADYX
16 GF Score
Price $0.00
View Full Analysis

What is Adynxx Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adynxx  (OTCPK:ADYX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Adynxx Cyclically Adjusted PS Ratio Related Terms


Adynxx Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Adynxx's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adynxx Cyclically Adjusted PS Ratio Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ADYX vs TRPX, MITI, RASP: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Adynxx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Adynxx's Cyclically Adjusted PS Ratio falls into.


ADYX
16GF Score
Adynxx Inc ADYX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adynxx Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Adynxx's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Adynxx's adjusted Revenue per Share data for the three months ended in Sep. 2019 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=0/256.7590*256.7590
=0.000

Current CPI (Sep. 2019) = 256.7590.

Adynxx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200912 12.051 215.949 14.328
201003 7.897 217.631 9.317
201006 7.321 217.965 8.624
201009 3.711 218.439 4.362
201012 5.224 219.179 6.120
201103 5.234 223.467 6.014
201106 10.734 225.722 12.210
201109 5.250 226.889 5.941
201112 2.013 225.672 2.290
201203 2.333 229.392 2.611
201206 2.943 229.478 3.293
201209 4.156 231.407 4.611
201212 4.167 229.601 4.660
201303 3.960 232.773 4.368
201306 4.798 233.504 5.276
201309 3.712 234.149 4.070
201312 3.065 233.049 3.377
201403 2.869 236.293 3.117
201406 4.083 238.343 4.398
201409 5.724 238.031 6.174
201412 6.351 234.812 6.945
201503 7.888 236.119 8.578
201506 6.761 238.638 7.274
201509 9.321 237.945 10.058
201512 8.762 236.525 9.512
201603 8.697 238.132 9.377
201606 9.384 241.018 9.997
201609 9.309 241.428 9.900
201612 9.453 241.432 10.053
201703 8.057 243.801 8.485
201706 0.817 244.955 0.856
201709 0.630 246.819 0.655
201712 0.833 246.524 0.868
201803 0.759 249.554 0.781
201806 1.176 251.989 1.198
201809 0.419 252.439 0.426
201812 0.554 251.233 0.566
201903 0.155 254.202 0.157
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adynxx Business Description

Address 100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
16GF Score

Get the complete analysis for ADYX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price